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Abstract 
Background: Egress of a number of different virus species from infected cells depends on proteins of the endosomal 
sorting complexes required for transport (ESCRT) pathway. HIV has also hijacked this system to bud viruses outward 
from the cell surface. How ESCRT-I activates ESCRT-III in this process remains unclear with conflicting published evi-
dence for the requirement of ESCRT-II which fulfils this role in other systems. We investigated the role of ESCRT-II using 
knockdown mediated by siRNA and shRNA, mutants which prevent ESCRT-I/ESCRT-II interaction and a CRISPR/Cas9 
EAP45 knockout cell line.
Results: Depletion or elimination of ESCRT-II components from an HIV infected cell produces two distinct effects. The 
overall production of HIV-1 Gag is reduced leading to a diminished amount of intracellular virion protein. In addition 
depletion of ESCRT-II produces an effect similar to that seen when ESCRT-I and -III components are depleted, that of a 
delayed Gag p26 to p24 +p2 cleavage associated with a reduction in export of virion particles and a visible reduction 
in budding efficiency in virus producing cells. Mutants that interfere with ESCRT-I interacting with ESCRT-II similarly 
reduce virus export. The export defect is independent of the decrease in overall Gag production. Using a mutant virus 
which cannot use the ALIX mediated export pathway exacerbates the decrease in virus export seen when ESCRT-II is 
depleted. ESCRT-II knockdown does not lead to complete elimination of virus release suggesting that the late domain 
role of ESCRT-II is required for optimal efficiency of viral budding but that there are additional pathways that the virus 
can employ to facilitate this.
Conclusion: ESCRT-II contributes to efficient HIV virion production and export by more than one pathway; both by 
a transcriptional or post transcriptional mechanism and also by facilitating efficient virus export from the cell through 
interactions with other ESCRT components.
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Background
Budding of human immunodeficiency virus-1 (HIV-
1) from an infected cell is known to be mediated by the 
endosomal sorting complexes required for transport 
(ESCRT) machinery recruited by either TSG101/Vps23 
(human protein and yeast homologue, respectively) of 
ESCRT-I and/or ALIX, both via the p6 domain of Gag, 
the major structural protein of the core of HIV [1]. The 
amino acid motifs in p6 critical for these two pathways 
are PTAP and YPXnL (where X refers any amino acid 
and n  =  1–3 residues; abbreviated to YPXL hereafter), 
respectively. Both pathways require the downstream 
ESCRT-III and VPS4 ATPase. ALIX is able to recruit 
CHMP4 of ESCRT-III directly, however its contribution 
to HIV-1 budding appears to be minimal in certain cell 
lines unless it is overexpressed [2–4]. For the pathway 
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mediated by TSG101, the link between ESCRT-I and 
-III is unclear. In yeast, ESCRT-I, -II and -III act con-
secutively in the formation of multivesicular bodies and 
ESCRT-II is crucial for the activation of ESCRT-III [5].
ESCRT-II is a Y-shaped complex comprised of two 
EAP20/Vps25 subunits, each forming one arm, and one 
copy each of EAP30/Vps22 and EAP45/Vps36 which 
together form the third arm [6–8]. ESCRT-II binds 
to ubiquitinated cargos and to membranes [7, 9, 10]. 
Together with ESCRT-I, it deforms membranes and 
induces bud formation in  vitro [11]. Both copies of the 
ESCRT-II subunit EAP20/Vps25 are required to induce 
conformational changes and to activate ESCRT-III 
CHMP6/Vps20 for membrane scission [8, 12, 13].
In the context of HIV-1 budding, previous reports 
showed that siRNA mediated depletion of the ESCRT-II 
subunit EAP20 did not appear to affect virus or virus-like 
particle (VLP) release [14, 15] and it was concluded that 
the infectivity of viruses was unaffected up to 48  h after 
knockdown [14]. Effects at later time points were not 
investigated in detail although knockdown of CHMP6 
reduced infectious HIV-1 production four to five fold at 
48 h; this however was ascribed to a general effect on pro-
tein trafficking. More recently, using a giant unilamellar 
vesicular system and full length myristylated HIV-1 Gag, 
it was shown that whereas ALIX can directly recruit the 
key ESCRT-III subunit CHMP4, ESCRT-I can only recruit 
CHMP4 when ESCRT-II and CHMP6 are present as inter-
mediary factors [16]. ESCRT-II was also believed to be 
dispensable for normal cytokinesis [17] but a more recent 
report shows that EAP20/Vps25 is required for the recruit-
ment of CHMP6 for ESCRT-mediated abscission [18].
Following an initial observation that ESCRT-II knock-
down appeared to inhibit HIV-1 production we ana-
lysed its role in viral replication using a range of assays 
including: knockdown with interfering RNA, dominant 
negative protein expression and the use of an EAP45 
knockout cell line. We present evidence consistent with 
ESCRT-II having at least two roles in efficient HIV-1 pro-
duction, one of which is enhancement of viral budding.
Results
Knockdown of ESCRT‑II with shRNA reduces the production 
of infectious virus
To minimise confounding off-target effects from indi-
vidual short hairpin RNAs (shRNA) and to serve as 
independent controls for the same target, up to three 
shRNA expression plasmids were constructed target-
ing the individual subunits of ESCRT-II (Table  1). They 
were transiently transfected into cells. We confirmed by 
Western blot at 96 h post transfection that cell viability 
was not affected by the knockdowns (Fig. 1a) and that the 
targeted subunits of ESCRT-II were effectively depleted 
(Fig.  1b, c, d). In agreement with previous publications, 
we also noted that the expression of ESCRT-II proteins 
was mutually dependent; knockdown of one ESCRT-II 
subunit led to a reduction of all three (data not shown) 
[19, 20]. We validated the shRNA system for the study of 
virus replication using DDX3 as a positive control (Addi-
tional file  1: Figure S1) [21]. To assess ESCRT-II in the 
context of a single cycle of virus replication we cotrans-
fected into cells a combination of plasmids capable of 
producing vesicular stomatitis virus-glycoprotein (VSV-
G)-pseudotyped HIV-1 together with shRNA expression 
vectors targeting one each of the ESCRT-II components. 
We measured production of HIV Gag p24 capsid (CA) 
protein and its release using a CA-p24 ELISA. The infec-
tivity of the pseudotyped particles generated from cells 
was analysed by TZMbl infectivity assay. By 48  h there 
was evidence of inhibition of both p24 production and 
virion infectivity (Additional file  2: Figure S2). Follow-
ing a media change at 72 h this was more readily seen at 
96  h by which time all the shRNAs that had effectively 
knocked down their targets also caused significant inhi-
bition of viral replication (Fig. 1e, f, g).
To ensure that this was not an artefact of the VSV-
pseudotype system the experiment was repeated using 
wild type HIV. Virus production was again analysed 
96 h post-transfection and similar results were obtained 
(Fig. 1h, i, j). Knock down of individual ESCRT-II com-
ponents thus impairs HIV-1 protein production. There 
is a decrease in intracellular p24 protein detected but, 
most markedly by 96 h, we also noted a relatively greater 
decline in supernatant p24 and viral infectivity compared 
to the fall in intracellular p24 suggestive of an additional 
budding defective phenotype.
Table 1 Sequences targeted by  the shRNA expression 
plasmids used
The target sequence for shControl was derived from Dharmacon ON-TARGETplus 
siRNA. The remaining were selected using Clontech RNAi Target Sequence 
Selector (http://bioinfo.clontech.com/rnaidesigner/sirnaSequenceDesignInit.do) 
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Fig. 1 Inhibition of infectious virus production by knockdown of ESCRT-II. a Cell viability upon knockdown of ESCRT-II subunits was determined 
using CellTiter-Glo Luminescent Cell Viability Assay (Promega, n = 2) and normalised to that of the non-transfected control (no-tf ). Cells treated 
with blasticidin served as a control for the viability assay. b–d Knockdown of ESCRT-II subunits in HeLaM cells. Cells were transfected with 50 ng 
shRNA expression plasmids using Fugene HD (Roche). Cells were harvested 96 h post-transfection and the levels of EAP20, EAP30 and EAP45 were 
analysed by Western blots. Detection of β-actin and α-tubulin showed equal loading. e–j Production of infectious pseudotyped (e–g) and wild type 
viruses (h–j) upon knockdown of ESCRT-II subunits: EAP45 (e, h), EAP20 (f, i) and EAP30 (g, j). The levels of supernatant (s/n p24) and intracellular 
(i/c p24) CA-p24 were quantified using ELISA. Virus infectivity was determined by infecting TZMbl cells with equal volumes of supernatant from the 
virus-producing HeLaM cells. Pseudotyped virus (e–g) was harvested at 96 h post-transfection (n ≥ 3). Wild type virus (h–j) was harvested at 96 h 
post-transfection (n ≥ 2). All bars represent the standard error of the mean (SEM); n = number of independent experiments. Unpaired, two-tailed 
Student’s t test with unequal variance was performed. In all figures *p < 0.05; **p < 0.01; ***p < 0.001.
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Disrupting ESCRT I/ESCRT‑II interaction inhibits production 
of infectious virus
The EAP45 component of human ESCRT-II contains a 
GLUE (GRAM-like ubiquitin-binding in EAP45) domain 
followed by the linker H0 helix, a helical domain (HD) 
and two winged helix (WH) domains (Fig. 2a) [7]. EAP45 
binds to ubiquitin via its GLUE domain [22]. Together 
with EAP30, the EAP45 GLUE domain also targets 
ESCRT-II to endosomal and non-endosomal membranes. 
Moreover, the H0 helix plays an important role for 
ESCRT-II binding to VPS28 of ESCRT-I. A four amino 
acid mutation in H0 (H0m) substantially reduced the 
interaction in  vitro [7]. An isolated GLUE domain was 
also not sufficient to interact with ESCRT-I [7].
We used two mutants (an isolated GLUE domain and 
the EAP45 mutant IERK159-162AAAA, designated H0m 
below) to seek evidence of a direct interaction occurring 
between ESCRT-I and ESCRT-II in HIV particle bud-
ding. As determined by Western blot, transfection of 
GLUE alone led to overexpression (Fig. 2b). H0m trans-
fected and untransfected cells showed no difference in 
EAP45 expression levels due to interdependency of the 
ESCRT-II subunits (data not shown). The untagged H0m 
could not be distinguished from wild type EAP45 on 
Western blot due to the few amino acid changes, but an 
HA-tagged variant verified that the mutations in H0m 
did not prevent its expression (Fig. 2c). The transfection 
of either mutant did not affect cell survival (Fig. 2d).
Viral plasmids were co-expressed with either wild type 
EAP45 or one of the two mutant EAP45 proteins. Com-
pared to cells transfected with the control firefly lucif-
erase, wild type EAP45 had no effect on the production 
of infectious wild type virus (Fig. 2e). By contrast, overex-
pression of GLUE or expression of H0m, significantly and 
reproducibly resulted in a decline in intracellular p24 but 
a proportionally larger fall in extracellular p24 and virion 
infectivity at 96  h post-transfection (Fig.  2e). Since the 
GLUE domain is the cargo-binding domain of ESCRT-
II and both GLUE and H0m interact less efficiently with 
ESCRT-I than with EAP45 [7], their expression in HIV-
1-producing cells likely diverted cargos that are relevant 
to viral particle production from the ESCRT machinery. 
Thus a direct interaction between ESCRT-I and ESCRT-
II would appear to facilitate the normal production of 
infectious HIV-1.
Knockdown of either TSG101 or EAP20 produces a similar 
phenotype
We further investigated the involvement of ESCRT-II in 
HIV budding using siRNA targeted against EAP20 and 
compared it to disrupting ESCRT-I. As expected knock-
down of TSG101 led to a late domain defective pheno-
type with reduced virus export and impaired terminal 
cleavage of p24/p2 to p24 (Fig.  3a). This was shown by 
Western blot and confirmed by image analysis (data not 
shown) and ELISA (Fig.  3b, c) and the measurements 
converted into a ‘release ratio’. Strikingly the same phe-
notype of Gag processing and virus release was evident in 
the EAP20 knockdown cells, again supporting a role for 
ESCRT-II in HIV budding from the cell in concert with 
ESCRT-I.
Knockdown of ESCRT‑II has an additive effect on release 
of YPXL mutant virus
If inhibiting viral export by reducing ESCRT-II is occur-
ring through interference with the PTAP pathway, as 
occurs with TSG101 knockdown, then blocking the alter-
native ALIX pathway should produce an additive effect 
when ESCRT-II is depleted. To investigate this possibility 
we used a Gag protein mutated in the YPXL motif [27]. 
This mutation of YPXL does not affect viral gene expres-
sion (Additional file 3: Figure S3A). We observed a reduc-
tion in virus release upon EAP20 knock down similar to 
that seen when TSG101 is depleted (Additional file 3: Fig-
ure S3B, C). We followed the effects on the release ratio 
in ‘real time’ by performing pulse chase experiments. 
The YPXL mutation shows reduced virion export which 
is further exacerbated when either TSG101 or EAP20 is 
depleted by siRNA reduction, compared to WT (Fig. 4), 
consistent with the previous observations. The degree of 
perturbation detected is modest but this likely relates to 
the relatively fast kinetics of virion assembly relative to 
the time points of the chase.
Virus production is affected in CRISPR/Cas 9 EAP45 
knockout cells
Interfering RNA experiments have potential drawbacks 
in that there may be incomplete knockdown of the 
target protein and that only very low levels of the fac-
tor targeted may be sufficient to carry out the process 
being probed. We sought to eliminate these concerns 
using a CRISPR/Cas 9 knock out EAP45 HAP1 cell 
line constructed by targeting exon 3 of the EAP45 gene 
(NM_016075). Sanger sequencing confirmed the 20 nt 
deletion within exon 3 (Additional file  4: Figure S4A). 
Parental and EAP45 knockout (KO) HAP1 cells were 
seeded in a 24 well plate and cells were transfected with 
pseudotyped HIV. The transfection efficiency is compa-
rable as evidenced by the similar level of GFP express-
ing cells (Additional file  4: Figure S4B). The viability of 
KO cells is similar with that of parental cells suggesting 
that absence of EAP45 does not cause deleterious effects 
on cell proliferation (Additional file 4: Figure S4C). 48 h 
post transfection, cells were lysed and supernatant har-
vested for virion purification. Western blot demon-
strates a decrease in p24 associated viral products from 
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the EAP45 knockout cell line compared to the parental 
cell control (Fig.  5). This result is consistent with the 
shRNA knockdown experiment where a reduction in 
intracellular p24 was also observed (Fig.  1). To further 
investigate at what stage this occurs, the HAP1 cells 
were infected with equivalent amounts of pseudotyped 
HIV-1 vector and the amount of HIV specific RNA tran-
scripts was measured 24  h post infection by visualisa-
tion under fluorescence microscopy using Quasar® 570 
Dye labelled multiple oligonucleotide probes (Fig.  6a). 
The fluorescence intensity at 300 ms exposure time was 
measured. The level of HIV RNA is noticeably decreased 
Fig. 2 Reduction in infectious virus production by EAP45 mutants. a Domain organisation of EAP45 and mutants used in this study. b Western blot 
detecting the expression of GLUE as a 16 kDa protein by a polyclonal rabbit anti-EAP45 antibody. c HA-tagged wt or H0M EAP45 expression plas-
mids were transfected into the cells. The level of expression was visualised by Western blot using anti-HA antibody. Tubulin is served as a loading 
control. d Cell viability assay performed as described for Fig. 1a. e Productions of infectious wild type viruses upon co-transfection of EAP45 mutants 
harvested 96 h post-transfection are shown. Transfections and analyses were performed as in Fig. 1. Error bars representing the SEM from up to six 
replicates are shown.
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in the HAP1 knockout cell line in comparison with that 
of the control cell line (Fig. 6b). This would be consistent 
with a defect in transcription caused by EAP45 knock-
out. A decline in Gag protein causing a reduced stabil-
ity of genomic RNA would be unlikely to account for the 
reduced detection of RNA seen as much of the signal is 
nuclear and Gag/genomic RNA interactions in HIV are 
not thought to occur within the nucleus.
A role for EAP45 solely at a transcriptional or early 
post transcriptional stage would not explain the dispro-
portionate decrease in virion release from ESCRT-II 
knocked down cells compared to the intracellular levels 
of viral p24 protein (Fig.  1). In addition the rate of Gag 
processing appeared to be impaired in the EAP45 knock-
out cells, especially the terminal cleavage of p24/p2 to 
p24 compared to the parental cells (Fig. 5).
To explore this further we compared virus export in 
the HAP1 EAP45 knockout and HAP1 wild type cells. 
Identical numbers of each cell type were transfected with 
pseudotyped HIV expressing either wild type Gag or 
PTAP mutated Gag. 48  h after transfection, the super-
natant was collected and virions purified by ultracen-
trifugation; cells were lysed for Western blot analysis. 
As expected, the PTAP mutant produced less virions 
from both cell types (Fig.  7a). However in addition we 
noted a disproportionate decrease in virus export from 
the EAP45 knockout cells (Fig.  7b). Quantitation of the 
release ratio after normalisation to the total p24-asso-
ciated viral products shows that there is a significant 
reduction in virion release from EAP45 knockout cells 
(Fig. 7c). This suggests that while ESCRT-II is not abso-
lutely required for budding its presence promotes effi-
cient virion release. Knock out of EAP45 produces a 
defect in the final cleavage of p24 from p24-p2 (Fig. 7d) 
substantiating the involvement of ESCRT-II at the final 
stage of virus budding.
Fig. 3 EAP20 is involved in virus release. a 293T cells were transfected with siControl, siTSG101 or siEAP20. Plasmids generating HIV pseudotyped 
with VSV-G were co-transfected with the second dose of siRNA post 24 h transfection. 48 h post second transfection total cell lysates were har-
vested and the supernatant was cushion-purified followed by Western blot analyses. b The supernatant extracellular p24 from WT transfected cells 
under each condition was normalised to that of siControl. c Extracellular p24 is divided by intracellular p24 to give the release ratio before being 
normalised to siControl. Error bars represent the SEM from six replicates. Statistical analyses were done using two-tailed Student t test with the statis-
tical significance shown by asterisks.
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Defects in late domain pathways typically manifest as 
a failure to complete the viral budding process with sig-
nificant numbers of virions arrested at an early stage of 
export at the plasma membrane. We examined viral bud-
ding by transmission electron microscopy in the parental 
and EAP45 knockout cell lines (Fig. 8). While virions can 
be seen budding normally from the wild type cells with 
free virus in the intercellular spaces, in the EAP45 knock-
out cells there are multiple incompletely budded virions 
detectable at the plasma membrane. This phenotype 
is very similar to that seen in other late domain defects 
[23–27] and provides strong evidence for the involve-
ment of ESCRT-II in the budding process.
Discussion
The ESCRT machinery was originally discovered in yeast 
where it was found to be essential for the sorting of car-
gos into intraluminal vesicles for degradation. Studies 
in yeast and in vitro reconstitution experiments showed 
that ESCRT-0, I, -II, -III and the Vps4-Vta1 complexes are 
sequentially involved in this pathway (reviewed in [28]). 
ESCRT-II proteins are crucial for this; overexpression of 
ESCRT-II rescues yeast ESCRT-I deletion mutants but 
not vice versa [29].
Humans possess a conserved homologous pathway 
and the role of ESCRT in HIV-1 budding is well estab-
lished [1] with recent evidence suggesting a scaffolding 
Fig. 4 Pulse-chase experiment on YPXL mutant and WT viruses showing the virus production is affected after TSG101 or EAP20 is knocked down. 
a Total cellular lysates and supernatants were harvested at time points 0, 1.5 and 3 h post pulsing under siTSG101, siEAP20 or siControl conditions 
followed by IP and SDS-PAGE using p24 specific antibody. The predicted viral protein sizes are noted at the left. b The release ratio was defined as 
the viral protein in the virions divided by that in the total cell lysates. The ratio at each time point was then normalised against that of YPXL mutant 
under siControl conditions at 3 h. The error bars represent the SEM and were calculated based on three replicates.
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interaction between the viral Gag protein and ESCRT 
components at the site of virus assembly [30]. The 
involvement of ESCRT-II has been the subject of debate 
for HIV and certain other systems. Specific cellular car-
gos including ferroportin [31] and CXCR4 [19] require 
ESCRT-II for their lysosomal degradation following 
internalisation, while others (Kaposi sarcoma-associated 
herpesvirus ubiquitinated MHC-I) do not [20]. For epi-
dermal growth factor receptor (EGFR), one of the most 
widely studied ESCRT cargos, the data are conflicting 
[14, 19, 20].
Budding and release of HIV-1 is a topologically simi-
lar process to endosomal vesicle formation in which the 
membrane also evaginates from the cytoplasm. ESCRT-
I, -III and the ESCRT-associated protein ALIX have been 
firmly implicated in the process. The p6 region of Gag 
contains two late domains, the PTAP and YPXL motifs 
that bind TSG101 and ALIX, respectively (reviewed in 
[32, 33]). Both of the TSG101 and ALIX pathways require 
the recruitment of certain ESCRT-III subunits and 
VPS4 ATPase [34, 35]. ALIX is able to recruit ESCRT-III 
directly [36], however in certain cell lines its contribu-
tion to HIV-1 budding is a minor one unless it is overex-
pressed [4, 37]. For the predominant pathway mediated 
by TSG101, the link between ESCRT-I and -III is still 
unclear. Langelier et  al. concluded that HIV-1 release 
was ESCRT-II-independent since the depletion of the 
ESCRT-II subunit EAP20 by small interfering RNA did 
not appear to cause a significant effect on viral release 
and infectivity as measured up to 48  h post transfec-
tion in a pseudotyped viral system. A similar phenotype 
was noted using wild type virus harvested at 24  h post 
transfection. They did however report that, at delayed 
time points, knockdown of ESCRT-II had a deleterious 
effect on virus production [14]. Pincetic et  al. showed 
that the fusion of EAP20 or EAP45 to the C-terminal of 
HIV-1 Gag containing a PTAP motif mutation did not 
rescue budding of virus-like particles whereas it did res-
cue ASLV [15]; their work also highlighted the different 
cell membranes involved in budding used by HIV and 
ASLV. It is unknown however whether the fused EAP20 
and EAP45 used in their studies were properly folded 
and fully functional. Two copies of EAP20 are required 
to activate ESCRT-III [8, 12, 13] and isolated EAP45 is 
unstable without the other ESCRT-II partners due to 
its extensive exposed hydrophobic regions [7, 8, 19, 20]. 
How ESCRT-III is activated without ESCRT-II was unex-
plained [28]. Recently however a reconstituted assembly 
model of HIV using myristylated Gag and giant unilamel-
lar vesicles, presented evidence that ESCRT-II was nec-
essary for the TSG101-mediated pathway to function for 
viral particle assembly [16].
We have now used several established and novel 
approaches to study this controversial area including two 
different knockdown protocols with two different viral 
strains in different cell lines and also a CRISPR/Cas  9 
EAP45 knockout cell line. In both HeLaM and 293T cell 
lines a defect was observed in viral export when ESCRT-
II was knocked down. Importantly in no case was there a 
detectable decrease in cell viability at the late time points 
assayed, indicating that our findings were specific and did 
not reflect a generalised effect on vesicular sorting in the 
cell (Figs.  1a, 2d, Additional file  4: Figure S4C). EAP20 
plays an important role in recruiting CHMP6 for correct 
cytokinesis [18] and the expression of ESCRT-II com-
ponents is mutually dependent [19, 20 and this study]. 
However, the depletion of EAP45 does not noticeably 
affect cell proliferation suggesting the level of EAP20 is 
sufficient for normal cell division.
In HeLaM cells the effect of EAP45 knockdown on viral 
budding was masked to some extent by a decline in Gag 
production as measured by intracellular p24 (Fig. 1) but 
this decrease can now be explained as ESCRT-II appears 
to have an additional earlier effect on HIV protein pro-
duction (Figs.  5, 6). Both knockdown and knockout 
experiments document a decline in intracellular Gag pro-
duction indicating that there may be a transcriptional or 
post transcriptional effect of ESCRT-II. The magnitude of 
Fig. 5 Intracellular Gag is reduced in HAP1 KO cell line. a Cells were 
transfected with plasmids able to produce pseudotyped HIV. 48 h 
after transfection, the supernatant was removed and cells were lysed 
for Western blot analyses. GAPDH was a loading control. Viral Gag 
products are labelled at the left. b Quantitation of Western blots 
shown in a using Image J. The total p24-associated viral products 
were quantified and the sum normalised to that of GAPDH preceded 
by normalisation to WT. Error bar represents SEM from five replicates 
and statistics were done by using a paired two-tailed Student t test; 
statistical significance is shown by the asterisk.
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this effect seems to be cell type dependent. In 293T cells, 
the total p24-associated viral products are relatively unaf-
fected (data not shown) consistent with a previous report 
[14]. However, in HelaM and HAP1 cells a more signifi-
cant decrease in p24-associated viral products is seen 
(Figs. 1, 5). ESCRT-II has been shown to have transcrip-
tional effects in other systems [38] but this has not been 
investigated in detail in the context of HIV. Despite the 
reduction in Gag production partially obscuring the later 
budding effect to some degree the latter is strikingly clear 
in the EAP45 knockout cell line (Figs.  7, 8) suggesting 
that ESCRT-II although not indispensable for production 
of infectious virus, contributes significantly to efficient 
particle release.
Viruses released from the PTAP mutated provirus 
transfected cells may be using the intact YPXL-ALIX 
pathway. Interestingly the fold reduction in release ratio 
between WT and PTAP mutant from the control cell line 
is similar to that from the knockout cells suggesting the 
proportion of viruses using YPXL-ALIX pathway is unal-
tered. The additive defect in infectious virus production 
observed after TSG101 or EAP20 are knocked down in 
the context of a co-transfected YPXL mutant virus, sug-
gests that both TSG101 and EAP20 are indeed involved 
in the budding process (Additional file 3: Figure S3, Addi-
tional file 4: Figure S4). The time course release ratio from 
pulse-chase experiments corroborates this (Fig.  4). The 
effect seen is less dramatic but pulse chase conditions 
Fig. 6 RNA FISH analyses of HIV infected HAP1 cells. a The same number of either HAP1 control cells or HAP1 knockout cells was infected with 
pseudotyped HIV. 24 h after infection, the supernatant was removed and the cells subjected to RNA FISH analysis by fluorescence microscopy. b 
The area of each individual genomic RNA positive control or knockout cell was defined and the fluorescence intensity was quantitated using image 
J. A total number of 23 or 26 cells, respectively, was identified from either control cells or knockout cells in two experiments. The statistics were done 
using unpaired two-tailed Student t test with the statistical significance shown by asterisks.
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may be suboptimally sensitive to detection of alterations 
in viral assembly, which is very rapid [39, 40].
One of the hallmarks of the defect caused by inhibiting 
the ESCRT pathway is a generalised delayed rate of Gag 
processing which is especially marked at the final stage of 
cleavage of p24 from p24-p2 [2, 14, 27, 41]. We consist-
ently see the same defect in EAP20 depleted cells (Fig. 3, 
Additional file  3: Figure S3) and EAP45 knock out cells 
(Figs. 5, 7). Similar effects in Gag processing occur in the 
side by side TSG101 and EAP20 knockdown conditions. 
The exaggerated effect of a PTAP mutant transfected 
into the EAP45 knock out cell line (Fig. 7d) implies that 
ESCRT-I and ESCRT-II may play similar or complemen-
tary roles at the early stage of virus budding. Although 
not cell lines for which HIV is tropic, all of these mon-
olayer cells allow a precise assessment of a single step 
viral life cycle and facilitate standardisation of the infec-
tivity assay. In addition suspension cells such as lympho-
cytes are less easily synchronised and cell division might 
be affected by ESCRT-II knockdown, which would likely 
impinge directly on HIV replication. The findings from 
gene depletion experiments (Figs.  1, 3, 4, 5, 7) together 
Fig. 7 HIV budding is affected in EAP45 knockout HAP1 cells. a, b Both control and EAP45 knockout cells were transfected with either WT or PTAP 
deleted mutant (PTAP−) pesudotyped HIV. 48 h after transfection, the supernatant was collected for virion purification (b) and cells were lysed (a) 
for Western blot analysis. GAPDH was used as a loading control. The viral Gag products are labelled at the left. c The viral protein detected in a was 
quantified using Image J (NIH) and the release ratio was defined by the ratio of p24 associated viral products in virions divided by that in the cor-
responding cell lysate, normalised to the level of GAPDH. d The p24 and p24-p2 from either WT or PTAP− provirus transfected cells shown in a were 
quantified using Image J. The p24/p24-p2 processing rate is shown by calculating the comparative intensity of p24 and p24-p2. Error bars represent 
the SEM from four replicates. Statistical analyses were done using paired two-tailed Student t test with the statistical significance shown by asterisks.
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with a consistency of effect using a dominant nega-
tive interference approach (Fig.  2) strongly suggest that 
ESCRT-II contributes to efficient virus budding and pro-
duction of infectious HIV-1 and that the effect of ESCRT-
II is mediated through its interaction with ESCRT-I.
It has been suggested that the self-assembly of Gag is 
sufficient to deform the membrane into a bud making a 
role for ESCRT-II dispensable. However three dimen-
sional analysis of the viral budding site argues that 
ESCRT contributes to membrane deformation during 
the early stage of Gag assembly and that membrane scis-
sion is not the only role of ESCRT [26]. ESCRT-II partici-
pates in membrane deformation as shown by an in vitro 
reconstitution assay [11] and by modelling of the crystal 
structure of ESCRT-II-CHMP62 with membranes [12]. 
Our EM data confirm that in the absence of ESCRT-II 
components budding is slowed or arrested and help to 
resolve some of the controversy surrounding HIV virus 
release.
Conclusion
The ESCRT system of proteins is involved in more than 
one process of viral production in HIV-1. ESCRT-II con-
tributes to efficient transcriptional and/or post-transcrip-
tional generation of HIV Gag. Additionally, there is clear 
evidence that the presence of ESCRT-II makes a signifi-
cant contribution to the budding and viral export pro-




HeLaM, a derivative of HeLa cells [42] and 293T cell lines 
were obtained from ATCC. TZMbl, carrying two HIV-1 
LTR-driven reporter genes, firefly luciferase and E. coli 
β-galactosidase [43, 44], is a HeLa cell clone that stably 
expresses high levels of CD4 and CCR5 and was obtained 
from NIH AIDS Research and Reference Reagent Pro-
gram. The HAP1 EAP45 CRISPR/Cas 9 knockout and 
control cell lines were constructed and purchased from 
Haplogen GmbH, Vienna, Austria. They were grown in 
Iscove’s modified Dulbecco’s medium (IMDM) supple-
mented with 10% fetal calf serum (FCS). HeLaM, 293T 
and TZMbl cells were grown in Dulbecco’s modified 
Eagle medium (DMEM) supplemented 10% FCS. All cell 
lines were grown at 37°C and 5% CO2 incubator.
Plasmids
pSVC21∆BglII is derived from a pHXB2 infectious 
clone but with a BglII fragment in the env gene (7041–
7621) deleted [45, 46]. The BH10 strain was a kind gift of 
Michael Laughrea, McGill University, Canada. The analo-
gous BglII deletion provirus was created in BH10. YPXL 
and PTAP deletion mutants of pBH10∆BglII were con-
structed using site directed mutagenesis [27, 47]. pCMV-
VSV-G encodes the VSV glycoprotein for pseudotyping. 
pLAI is a full-length molecular clone of HIV-1 strain 
LAI for the expression of wild type virus [48]. pTER vec-
tor [49] was obtained from van der Wetering (Centre for 
Biomedical Genetics, The Netherlands) and was used for 
cloning shRNA into BamHI and XhoI sites to generate 
individual pTER-shRNA. pGEX4T1-EAP20, pGEX4T1-
EAP30, pGEX4T1-EAP45 [20] and pEGFPC2-HSV1TK 
were obtained for the cloning of genes of interest to pEF 
vector containing human elongation factor 1α according 
to Lee et al. [50]. Mutagenesis PCR was used to introduce 
the IERK 159-162 AAAA mutation in the H0 helix of 
EAP45 [7].
Fig. 8 Transmission electron microscopy of thin-sectioned parental 
(a) and EAP45 knockout cells (b) transfected with pseudotyped HIV. 
Note the free virions surrounding the active budding sites in a and 
tethered budding particles on the plasma membrane in b. Bar equals 
500 nm.
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Cell viability
The manufacturer’s protocol for CellTiter-Glo Lumi-
nescent Cell Viability Assay (Promega) was adapted for 
96-well half-area plates. Briefly, the cell culture plate was 
equilibrated at room temperature for 30  min. CellTiter-
Glo Reagent (50 µl) was added to each well and the plate 
was placed on an orbital shaker (750 rpm, Titramax 100, 
Heidolph) for 2 min to lyse cells. After a further 10-min 
incubation at room temperature, luminescence was read 
with a 1 s integration time using GloMax 96 Microplate 
Luminometer (Promega).
Pseudotyped and wild type virus production with shRNA 
or EAP45 expression
To produce pseudotyped virus, HeLaM cells of 50–80% 
confluency were co-transfected in a 24-well plate format 
with 44 ng pSVC21∆BglII and 15.6 ng pCMV-VSV-G in 
an optimised ratio of 3.7:1.3 using Fugene HD (Roche). A 
total amount of 200 ng pBH10∆BglII and pCMV-VSV-G 
was co-transfected into 50–80% HAP1 cells in a 24-well 
plate using TurboFectin 8.0 (Origene). For wild type 
virus, cells were transfected with 40 ng pLAI. Transient 
expression of shRNA was performed by co-transfecting 
pTER-shRNA with the viral plasmids. For pseudotyped 
virus, 120  ng shRNA expression plasmid together with 
the above mentioned quantities of DNA plasmids for 
pseudotyping were transfected. For wild type virus, 50 ng 
shRNA expression plasmid and 40 ng LAI were co-trans-
fected. In the EAP45 mutant experiments HeLaM were 
transiently co-transfected with 200  ng EAP45 mutant 
expression plasmids. 200  ng EAP45 mutant expression 
plasmids was also used for the wild type virus study. In 
all the above experiments, viruses were harvested at 48 
or 96 h post-transfection and the supernatant was used 
to infect TZMbl cells to assay for infectivity. The medium 
was replaced 24  h prior to harvesting at 96  h to study 
the released viruses at late point. Supernatant was inac-
tivated in Empigen (0.1%; Sigma-Aldrich) in PBS. Virus-
producing cells were lysed in 150 μl/well of 1% Empigen 
in Passive Lysis Buffer (Promega). Extracellular and intra-
cellular CA-p24 levels were quantified by ELISA (Aalto) 
with a slight modification [51].
Virus infectivity
Infectivity was based on the Tat-dependent upregulation 
of LTR-driven firefly luciferase expression upon HIV-1 
infection of TZMbl cells. Cells (~105) were seeded in 
24-well plates in 0.5 ml/well of complete DMEM. Equal 
volumes of medium from virus-producing cells were 
added to TZMbl cells. DEAE-dextran (50  µg/ml; Appli-
Chem) was added to facilitate infection. TZMbl cells 
were lysed at 48  h post-infection in 150  µl/well of Cell 
Culture Lysis Reagent (CCLR; Promega). Firefly luciferase 
expression was quantified using the Luciferase Assay Sys-
tem (Promega). Cell lysates (5  µl) were transferred to a 
white 96-well half-area plate. Luciferase Assay Reagent 
(25 µl) was added and the luminescence was measured by 
GloMax 96 Microplate Luminometer (Promega).
RNA FISH
Around 1 × 105 either HAP1 control or EAP45 KO cells 
were seeded in each well of an 8 well multi-well glass 
slide (Millipore). After 24 h, the cells were infected with 
HIV-VSV-G containing 200  ng supernatant p24. After 
24 h infection, the media was removed and washed once 
with PBS before fixing with formaldehyde in PBS (3.7%) 
for 10  min at room temperature. This was followed by 
washing with PBS and permeabilising with 70% ethanol 
at 4°C for 1  h. The probe set composing 37 oligonucle-
otides labelled with Quasar® 570 Dye at the 5′ end was 
purchased from Biosearch Technologies specifically tar-
geting HIV Gag coding region. The hybridisation process 
was followed according to manufacturer’s instructions. 
The vectashield was applied before the coverslip was 
mounted and visualised under Olympus Ix81 fluores-
cence microscope. The TRITC channel was used for 
genomic RNA visualisation. The images were taken by 
pre-setting at 300  ms exposure time. For fluorescence 
quantitation, the genomic RNA positive cells were identi-
fied and the area of each individual cell was defined and 
quantified using ImageJ (NIH).
siRNA knockdown
The Stealth siRNA (Life technologies) knockdown 
was performed using TransIT-TKO transfection rea-
gent (Mirus) based on the manufacturer’s instructions. 
Briefly, one well of 50% confluent 293T cells in a 24 well 
plate was transfected with 2 µl, 20 µM Stealth siRNA to 
EAP20, TSG101 or control using 2.5  µl TransIT-TKO. 
Total amount of 40 ng pBH10∆BglII and pCMV-VSV-G 
was mixed with 160 ng pBluescript empty vector and fol-
lowed by co-transfection with second dose of 2 µl, 20 µM 
siRNA 24 h post first dose transfection. The supernatant 
was collected 72 h post first dose transfection and clari-
fied by low centrifugation before ELISA for p24 quan-
titation or Optiprep cushion ultracentrifugation for 
virion purification for Western analysis. Total cells were 
lysed with 150  µl 1× CCLR before being subjected to 
ELISA and Western blot analysis using mouse monoclo-
nal antibodies to TSG101 (Abcam) and to HIV-1 p55/
p24 (ARP313, NIBSC) and rabbit polyclonal antibodies 
to GAPDH (Abcam) and EAP20 (P Luzio, Cambridge 
Institute for Medical Research, UK). Quantification of 
Western blots was performed using ImageJ (NIH). For 
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knockdown conditions for the pulse-chase experiments 
one well of fifty percent confluent 293T cells in a 6 well 
plate was transfected with 8 µl, 20 µM Stealth siRNA to 
EAP20, TSG101 or control using 10 µl TransIT-TKO. A 
total of 2  µg pBH10∆BglII and 135  ng pCMV-VSV-G 
was co-transfected with second dose of Stealth siRNA 
as above. After 48 h post first transfection, the cells were 
labelled with 35S protein labeling mix (Perkin-Elmer) as 
described in the pulse-chase method section.
Pulse‑chase analysis
Pulse-chase analysis was performed by adapting the 
method of L’Hernault et al. [52]. Briefly, 293T cells were 
transfected with 2 µg pBH10∆BglII and 135 ng pCMV-
VSV-G in 6-well plates. After 24  h, cells were washed 
and starved in 0.5 ml of DMEM lacking methionine and 
cysteine (Met-Cys-free DMEM; Sigma-Aldrich) supple-
mented with 4 mM glutamine and 10% FCS. Cells were 
then pulse-labelled for 30  min with 0.5  ml of Met-Cys-
free DMEM supplemented with 110  μCi of EasyTag 
Express 35S protein labeling mix (11  mCi/ml; Perkin-
Elmer). The medium was removed and supplemented 
with fresh complete DMEM with 2 mM Met and 2 mM 
Cys when time point zero was set. Cells were chased at 90 
and 180 min post labelling. At each time point the virus-
containing supernatants were harvested and clarified 
by low speed centrifugation. Cells were lysed with RIPA 
buffer (50  mM Tris–HCl [pH 7.5], 100  mM NaCl, 1% 
sodium deoxycholate, 0.1% SDS, 1% Triton X-100, pro-
tease inhibitor cocktail [Roche]). The capsid and Gag pro-
teins were immunoprecipitated using 3.25 µg anti-HIV-1 
p55/p24 mouse monoclonal antibody (ARP313, NIBSC) 
at 4°C. Protein G-Sepharose beads (Sigma-Aldrich) were 
then added to the mixtures for a further 1  h rotation 
before being spun and washed in RIPA buffer. Finally, 
the beads were resuspended in 50 μl 2× Laemmli buffer. 
Samples were boiled for 5 min before being loaded onto 
a 15% SDS-polyacrylamide gel. Gels were fixed and dried 
prior to autoradiography. Quantification was performed 
using ImageJ (NIH).
Electron microscopy of budding virus
The HAP1 control cells and KO cells were transfected 
as described above. 48 h post transfection, the superna-
tant was removed and the monolayer of cells was washed 
with 9% NaCl followed by fixation in 2% glutaraldehyde 
and 2% formaldehyde in 0.05  M cacodylate buffer over-
night. The cells were scraped and collected by centrifu-
gation before being embedded and thin-sectioned. The 
thin-sectioned samples were mounted on an EM grid and 
visualised using a Tecnai G2 electron microscope. Images 
were taken at 3,500× magnification.
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Additional files
Additional file 1: Figure S1. Validation of shRNA system for the study 
of HIV-1 replication. (A) Western blot detecting the knockdown of DDX3 
by shDDX3 (target sequence CATTGAGCTTACTCGTTAT) in HeLaM cells. (B) 
Cell viability assay performed as described for Figure 1A. (C-D) Produc-
tion of infectious pseudotyped (c, mean ± SEM, n = 4) and wild type 
(d, mean ± SD of duplicate samples) viruses upon knockdown of DDX3, 
96 h post-transfection. Transfections and analyses were performed as 
described for Figure 1.
Additional file 2: Figure S2. Inhibition of pseudotyped virus produc-
tion by knockdown of ESCRT-II. As for Figure 1 (A: EAP45; B: EAP20; C: 
EAP30) showing results at 48 h post transfection.
Additional file 3: Figure S3. Budding effects from YPXL− transfected 
cells upon knocking down TSG101 or EAP20. (A) as described in Figure 3A 
except YPXL mutant provirus was used in the transfection. (B) The 
supernatant extracellular p24 from YPXL− transfected cells under each 
condition was normalised against to that of WT siControl from Figure 3. 
(D) Extracellular p24 is divided by intracellular p24 to give the release 
ratio before being normalised to WT siControl from Figure 3. Error bars 
represent the SEM from six replicates.
Additional file 4: Figure S4. Characterisation of CRISPR/Cas9 EAP45 
knockout HAP1 cell line. (A). Sanger sequencing confirms that there is a 20 
nt deletion (underlined) in exon 3 of HAP1 EAP45 knockout cell line. (B). 
The transfection efficiency of both control and knockout cell lines were 
monitored by transfecting a eGFP expression construct. (C). Cell viability 
assay of WT provirus transfected HAP1 and KO cells. Non-transfected and 
blasticidin treated cells served as controls. The error bars represent the 
SEM from two replicates.
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